论文部分内容阅读
心血管疾病是终末期肾病维持血液透析(HD)患者的主要死因,ID患者严重左室肥厚发病率高且死亡率亦高。左室肥厚发生机理不明,肾性贫血、动脉高血压在其发生、发展和恶化中可能起关键作用。作者对HD患者随访至少1年,分析应用重组人类促红细胞生成素(r-huEPO)使贫血改善及调整血压对左室肥厚的影响。病人和方法12例终末期肾病维持HD患者,男8、女4例,年龄60.8±9.9岁,HD平均44.8个月,每周3次,每次透析3.5～5小
Cardiovascular disease is the leading cause of death in patients with end-stage renal disease who support hemodialysis (HD). ID patients have a high incidence and mortality of severe left ventricular hypertrophy. The mechanism of left ventricular hypertrophy is unknown, renal anemia, arterial hypertension may play a key role in its occurrence, development and deterioration. The authors followed up HD patients for at least one year and analyzed the effects of recombinant human erythropoietin (r-huEPO) on improving anemia and adjusting blood pressure on left ventricular hypertrophy. Patients and Methods Twelve patients with end-stage renal disease (HD), 8 males and 4 females, aged 60.8 ± 9.9 years and HD averaged 44.8 months, were enrolled in this study. Three times a week and 3.5 ~ 5 hours per dialysis